A Study of Experimental Medication BMS-986036 in Adults With Nonalcoholic Steatohepatitis (NASH) and Liver Cirrhosis
NCT ID: NCT03486912
Last Updated: 2022-10-13
Study Results
Outcome measurements, participant flow, baseline characteristics, and adverse events have been published for this study.
View full resultsBasic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
COMPLETED
PHASE2
155 participants
INTERVENTIONAL
2018-06-12
2021-09-14
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
A Study of Experimental Medication BMS-986036 in Adults With Nonalcoholic Steatohepatitis (NASH) and Stage 3 Liver Fibrosis
NCT03486899
A Study of BMS-986036 in Subjects With Non-Alcoholic Steatohepatitis (NASH)
NCT02413372
A Sub-study of BMS-986036 in Subjects With Non-Alcoholic Steatohepatitis (NASH)
NCT03400163
Safety and Effectiveness of BMS-986263 in Adults With Compensated Cirrhosis (Liver Disease) From Nonalcoholic Steatohepatitis (NASH)
NCT04267393
A Study of Experimental Medication BMS-986263 in Adults With Advanced Hepatic Fibrosis After Cure of Hepatitis C
NCT03420768
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
RANDOMIZED
PARALLEL
TREATMENT
QUADRUPLE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
BMS-986036 Dose Level 1
BMS-986036
Specified dose on specified days.
BMS-986036 Dose Level 2
BMS-986036
Specified dose on specified days.
BMS-986036 Dose Level 3
BMS-986036
Specified dose on specified days.
Placebo
Placebo
Specified dose on specified days.
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
BMS-986036
Specified dose on specified days.
Placebo
Specified dose on specified days.
Other Intervention Names
Discover alternative or legacy names that may be used to describe the listed interventions across different sources.
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* Must be taking anti-diabetic, anti-obesity, or anti-dyslipidemic medications must have been on stable regimens for at least 3 months (12 weeks) (6 weeks for statins) prior to and during the screening period
* Participants taking vitamin E at doses greater than or equal to (\>=) 800 IU/day must have been on stable doses for at least 6 months (26 weeks) prior to and during the screening period. Vitamin E treatment (\>=800 IU/day) must not have been initiated after the qualifying liver biopsy was performed
Exclusion Criteria
* Current or past history of hepatocellular carcinoma (HCC)
* Past or current evidence of hepatic decompensation (e.g., ascites, variceal bleeding, hepatic encephalopathy and/or spontaneous bacterial peritonitis) or liver transplantation
* Medical history of gastroesophageal varices, except if esophagogastroduodenoscopy \[EGD\] performed within 12 months prior to the Screening Period has shown \<= Grade 1 varices
18 Years
75 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Bristol-Myers Squibb
INDUSTRY
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Bristol-Myers Squibb
Role: STUDY_DIRECTOR
Bristol-Myers Squibb
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
North Alabama Health Research, LLC
Madison, Alabama, United States
Local Institution - 0005
Chandler, Arizona, United States
Local Institution - 0088
Phoenix, Arizona, United States
Local Institution - 0006
Phoenix, Arizona, United States
Local Institution - 0090
Tucson, Arizona, United States
Kindred Medical Institute for Clinical Trials
Corona, California, United States
Local Institution - 0092
Coronado, California, United States
Local Institution - 0038
La Jolla, California, United States
Local Institution - 0017
Los Angeles, California, United States
Cedars-Sinai Medical Center
Los Angeles, California, United States
GastroIntestinal Biosciences
Los Angeles, California, United States
Catalina Research Institute
Montclair, California, United States
Kaiser Permanente
Oakland, California, United States
Diverse Research Solutions
Oxnard, California, United States
Huntington Medical Research Institutes - HMRI Liver Center
Pasadena, California, United States
Local Institution - 0020
Pasadena, California, United States
Local Institution - 0073
Redwood City, California, United States
Local Institution - 0012
Rialto, California, United States
Local Institution - 0089
San Clemente, California, United States
Local Institution
San Diego, California, United States
Local Institution - 0014
San Diego, California, United States
Local Institution - 0068
San Francisco, California, United States
Local Institution - 0042
Bridgeport, Connecticut, United States
Local Institution
Washington D.C., District of Columbia, United States
Local Institution - 0079
Coral Gables, Florida, United States
Top Medical Research
Cutler Bay, Florida, United States
Clinical Research of Homestead
Homestead, Florida, United States
Mayo Clinic - Jacksonville
Jacksonville, Florida, United States
Local Institution - 0001
Lakewood Rch, Florida, United States
Local Institution - 0003
Miami, Florida, United States
A+ Research
Miami, Florida, United States
IMIC Research
Miami, Florida, United States
Sensible Healthcare
Ocoee, Florida, United States
Local Institution - 0081
Orlando, Florida, United States
Local Institution
Tampa, Florida, United States
Local Institution
Atlanta, Georgia, United States
Local Institution - 0108
Marietta, Georgia, United States
Tandem Clinical Research
Marrero, Louisiana, United States
Tulane University Health Sciences Center
New Orleans, Louisiana, United States
Local Institution - 0026
New Orleans, Louisiana, United States
Local Institution - 0010
Baltimore, Maryland, United States
Local Institution - 0058
Catonsville, Maryland, United States
Boston Medical Center
Boston, Massachusetts, United States
NECCR PrimaCare Research
Fall River, Massachusetts, United States
University of Michigan
Ann Arbor, Michigan, United States
Clinical Research Professionals
Chesterfield, Missouri, United States
Local Institution - 0031
Kansas City, Missouri, United States
Saint Louis University
St Louis, Missouri, United States
University at Buffalo
Buffalo, New York, United States
Northwell Health
Manhasset, New York, United States
Mount Sinai Hospital
New York, New York, United States
Local Institution - 0036
New York, New York, United States
Icahn School of Medicine at Mount Sinai
New York, New York, United States
Local Institution - 0067
Butner, North Carolina, United States
Local Institution - 0064
Charlotte, North Carolina, United States
Northeast GI Research Division
Concord, North Carolina, United States
University of Pennsylvania
Philadelphia, Pennsylvania, United States
Local Institution - 0009
Philadelphia, Pennsylvania, United States
Local Institution - 0004
Pittsburgh, Pennsylvania, United States
Local Institution
Chattanooga, Tennessee, United States
Local Institution - 0046
Germantown, Tennessee, United States
Local Institution - 0041
Hermitage, Tennessee, United States
Vanderbilt University Medical Center
Nashville, Tennessee, United States
Texas Clinical Research Institute
Arlington, Texas, United States
Local Institution - 0066
Austin, Texas, United States
Local Institution - 0051
Dallas, Texas, United States
Local Institution - 0053
Dallas, Texas, United States
Texas Digestive Disease Consultants - Dallas
Dallas, Texas, United States
University of Texas Southwestern Medical Center
Dallas, Texas, United States
Local Institution - 0084
Fort Worth, Texas, United States
Local Institution - 0002
Houston, Texas, United States
Local Institution - 0057
Houston, Texas, United States
Local Institution - 0063
Houston, Texas, United States
Local Institution - 0028
San Antonio, Texas, United States
Local Institution - 0011
San Antonio, Texas, United States
Local Institution - 0102
San Antonio, Texas, United States
University of Vermont Medical Center
Burlington, Vermont, United States
University of Virginia Health System
Charlottesville, Virginia, United States
Inova Fairfax Hospital
Falls Church, Virginia, United States
Gastroenterology Associates, PC
Manassas, Virginia, United States
Local Institution - 0069
Norfolk, Virginia, United States
The Gastroenterology Group
Reston, Virginia, United States
Bon Secours Liver Institute of Richmond
Richmond, Virginia, United States
Local Institution - 0077
Richmond, Virginia, United States
Local Institution - 0050
Richmond, Virginia, United States
Kurume University Hospital
Kurume, Fukuoka, Japan
Local Institution - 0055
Yokohama, Kanagawa, Japan
Local Institution - 0072
Kashihara, Nara, Japan
Toranomon Hospital
Minato, Tokyo, Japan
Keio University Hospital
Shinjuku-ku, Tokyo, Japan
Fukushima Medical University Hospital
Fukushima, , Japan
Countries
Review the countries where the study has at least one active or historical site.
References
Explore related publications, articles, or registry entries linked to this study.
Abdelmalek MF, Sanyal AJ, Nakajima A, Neuschwander-Tetri BA, Goodman ZD, Lawitz EJ, Harrison SA, Jacobson IM, Imajo K, Gunn N, Halegoua-DeMarzio D, Akahane T, Boone B, Yamaguchi M, Chatterjee A, Tirucherai GS, Shevell DE, Du S, Charles ED, Loomba R. Pegbelfermin in Patients With Nonalcoholic Steatohepatitis and Compensated Cirrhosis (FALCON 2): A Randomized Phase 2b Study. Clin Gastroenterol Hepatol. 2024 Jan;22(1):113-123.e9. doi: 10.1016/j.cgh.2023.04.012. Epub 2023 Apr 23.
Abdelmalek MF, Charles ED, Sanyal AJ, Harrison SA, Neuschwander-Tetri BA, Goodman Z, Ehman RA, Karsdal M, Nakajima A, Du S, Tirucherai GS, Klinger GH, Mora J, Yamaguchi M, Shevell DE, Loomba R. The FALCON program: Two phase 2b randomized, double-blind, placebo-controlled studies to assess the efficacy and safety of pegbelfermin in the treatment of patients with nonalcoholic steatohepatitis and bridging fibrosis or compensated cirrhosis. Contemp Clin Trials. 2021 May;104:106335. doi: 10.1016/j.cct.2021.106335. Epub 2021 Feb 28.
Provided Documents
Download supplemental materials such as informed consent forms, study protocols, or participant manuals.
Document Type: Study Protocol
Document Type: Statistical Analysis Plan
Related Links
Access external resources that provide additional context or updates about the study.
BMS Clinical Trial Information
BMS Clinical Trial Patient Recruiting
Investigator Inquiry Form
FDA Safety Alerts and Recalls
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
MB130-069
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.